Recombinant Methionyl Human Stem Cell Factor and Filgrastim for Peripheral Blood Progenitor Cell Mobilization and Transplantation in Non-Hodgkin's Lymphoma Patients — Results of a Phase I/II Trial

Craig H Moskowitz; Patrick Stiff; Michael S Gordon; Ian McNiece; Anthony D Ho; John J Costa; E. Randolf Broun; Robert A Bayer; Melody Wyres; Jerome Hill; Kathy Jelaca-Maxwell; Craig R Nichols; Sherri L Brown; Stephen D Nimer; Janice Gabrilove

doi:10.1182/blood.V89.9.3136

Back

Recombinant Methionyl Human Stem Cell Factor and Filgrastim for Peripheral Blood Progenitor Cell Mobilization and Transplantation in Non-Hodgkin's Lymphoma Patients — Results of a Phase I/II Trial

Journal article

Peer reviewed

Recombinant Methionyl Human Stem Cell Factor and Filgrastim for Peripheral Blood Progenitor Cell Mobilization and Transplantation in Non-Hodgkin's Lymphoma Patients — Results of a Phase I/II Trial

Craig H Moskowitz, Patrick Stiff, Michael S Gordon, Ian McNiece, Anthony D Ho, John J Costa, E. Randolf Broun, Robert A Bayer, Melody Wyres, Jerome Hill, …

Blood, Vol.89(9), pp.3136-3147

1997-05-01

DOI: https://doi.org/10.1182/blood.V89.9.3136

PMID: 9129016

Abstract

Abstract To examine the safety and efficacy of recombinant-methionyl human stem cell factor (r-metHuSCF), 38 patients with intermediate-grade or immunoblastic high-grade non-Hodgkin's lymphoma who were eligible for autologous transplantation were randomized to receive r-metHuSCF (5, 10, 15, or 20 μg/kg/d) plus Filgrastim (10 μg/kg/d) or Filgrastim (10 μg/kg/d) alone to mobilize peripheral blood progenitor cells. Subcutaneous administration of r-metHuSCF was well tolerated in conjunction with a multi-agent pre-medication regimen; local injection site reactions were the most commonly seen adverse event. The total mononuclear cell count, CD34+ cell content, granulocyte-macrophage colony-forming cells (GM-CFC), and burst-forming units-erythroid (BFU-E) per kilogram in the apheresis product was similar when all patients were analyzed by treatment cohort and mobilization regimen (Filgrastim or r-metHuSCF in combination with Filgrastim); however, when prior chemotherapy was taken into account in a supplementary analysis, clinically important differences were observed. Extensive prior therapy was defined as the amount of exposure to specific stem cell toxic chemotherapeutic agents that patients received. These agents include procarbazine, nitrogen mustard, melphalan, nitrosoureas (≥2 cycles of any of these drugs) or greater than 7.5 g of cytosine arabinoside. In these patients, there was an increased number of CD34+ cells (1.76 v 0.28 × 106/kg), GM-CFC (20.5 v 5.0 × 104/kg), and BFU-E (36.9 v 8.9 × 104/kg) in patients receiving r-metHuSCF and Filgrastim (N = 18) compared with Filgrastim alone (N = 5). These patients also had a decreased time to an untransfused platelet count of 20 × 109/L that was 10.5 days shorter in the patients who received r-metHuSCF and Filgrastim (12.5 v 23 days). These differences were not found to be statistically significant, possibly because of small size, but are clinically important.

Metrics

15 Record Views

88 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.606 Hematopoietic Stem Cells
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Recombinant Methionyl Human Stem Cell Factor and Filgrastim for Peripheral Blood Progenitor Cell Mobilization and Transplantation in Non-Hodgkin's Lymphoma Patients — Results of a Phase I/II Trial
Creators: Craig H Moskowitz - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Patrick Stiff - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Michael S Gordon - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Ian McNiece - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Anthony D Ho - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
John J Costa - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
E. Randolf Broun - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Robert A Bayer - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Melody Wyres - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Jerome Hill - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Kathy Jelaca-Maxwell - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Craig R Nichols - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Sherri L Brown - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Stephen D Nimer - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Janice Gabrilove - 1 From the Lymphoma Service and the Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Bone Marrow Transplant Program, Loyola University School of Medicine, Maywood, IL; Hematology/Oncology Division, Indiana University Medical Center, Indianapolis, IN; Stem Cell Transplant Program, University of California-San Diego Medical Center, San Diego; the Departments of Medicine and Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA; and Amgen Inc, Thousand Oaks, CA
Publication Details: Blood, Vol.89(9), pp.3136-3147
Academic Unit: Leadership Department; Miller School of Medicine; Sylvester Comprehensive Cancer Center; UMMG Department of Medicine
Language: English
Resource Type: Journal article
PMID: 9129016
Record Identifier: 991031562803002976